Skip to Main Content

After a two-year battle, a Dutch health insurer has won a lawsuit that accused AstraZeneca (AZN) of creating an unfair monopoly for one of its most popular medicines by relying on an invalidated patent to thwart lower-cost competition.

At issue was a patent for the antipsychotic tablet Seroquel, which the District Court of the Hague ruled AstraZeneca used to charge “unjustifiably” high prices to health insurers. In its 2018 lawsuit, the Menzis health insurer noted a patent had been invalidated, yet the drug maker attempted to enforce its patent rights and, consequently, a large competitor was forced to delay selling a generic version.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED